Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate?

详细信息    查看全文

• 作者：Pablo Martinez ; Alex Martinez-Marti ; Alejandro Navarro ; Susana Cedré ; s ; Enriqueta Felip ; ^{efelip@vhebron.net" class="auth_mail}
• 关键词：Non-small cell lung cancer ; Targeted therapies ; Early-stage ; Locally-advanced stage
• 刊名：Lung Cancer
• 出版年：May 2014
• 年：2014
• 卷：84
• 期：2
• 页码：97-100
• 全文大小：485 K

文摘

Non-small-cell lung cancer (NSCLC) represents approximately 85% of all lung cancer cases, with a world-wide annual incidence of around 1.3 million. Surgery remains the corner stone of treatment in early-stage NSCLC when feasible, and the addition of adjuvant cisplatin-based chemotherapy has improved these results in resected NSCLC patients. For those patients with non-metastatic NSCLC not suitable for complete surgical resection, chemotherapy plus radiotherapy remains the best treatment option. For patients with metastatic NSCLC, molecular targeted agents have become part of the therapeutic arsenal in recent years. However, to date no targeted agent has been approved for patients with early or locally-advanced stages of NSCLC. Here, we review the rationale, literature and studies addressing the role of targeted agents used in the adjuvant setting or as part of chemoradiotherapy regimens.